Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
FTC began the process to unionize back in 2023, raising concerns about their access to telework, potential politicization of the civil service and other issues.
Federal regulators have filed an administrative complaint against the St. Louis-based pharmacy benefit manager. Patients and ...
The Federal Trade Commission says a $48 million settlement should put an end to what it calls "predatory" tactics by the ...
Amid intense focus on AI and a flurry of consumer privacy law updates, legislative activity has continued to change data breach ...
The FTC launches Operation AI Comply to combat deceptive AI practices, targeting companies like DoNotPay and Ascend Ecom for ...
A Federal Trade Commission (FTC) report found that social and video streaming services pose serious privacy risks, especially ...
Cigna Group’s Express Scripts sued the US Federal Trade Commission over a recent report that the company said demonizes ...
In Kyocera Senco Industrial Tools Inc. v. International Trade Commission, the Federal Circuit held that an expert must meet the definition of ...
Iowa Attorney General Brenna Bird joined 11 other Republican attorneys general who filed a brief in federal court this week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback